Back to today’s briefing

Story perspectives

FDA-Approved Drug Halts Parkinson's Disease Progression in Mice

1/20/2025

41 4

Summary

Story summary

Researchers at Johns Hopkins University have uncovered a crucial link between cell surface proteins Aplp1 and Lag3 and the spread of toxic alpha-synuclein proteins tied to Parkinson's disease. Excitingly, an FDA-approved cancer drug, nivolumab/relatlimab, successfully halted this harmful interaction in mice, paving the way for new therapies to combat Parkinson's and other neurodegenerative disorders affecting over 8.5 million people worldwide.

1 of 1

Story summary

Researchers at Johns Hopkins University have uncovered a crucial link between cell surface proteins Aplp1 and Lag3 and the spread of toxic alpha-synuclein proteins tied to Parkinson's disease. Excitingly, an FDA-approved cancer drug, nivolumab/relatlimab, successfully halted this harmful interaction in mice, paving the way for new therapies to combat Parkinson's and other neurodegenerative disorders affecting over 8.5 million people worldwide.